Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1604)
  2. Meeting Abstract (791)
  3. Book Section (104)
  4. Review (72)
  5. Editorial (58)
  6. Research Letter (45)
  7. Guidelines (26)
  8. Conference Paper (22)
  9. Correspondence (21)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1690)
  2. Survivorship Research (1193)
  3. Solid Tumor Oncology Division (1052)
  4. Department of Pathology and Laboratory Medicine (957)
  5. Surgery (947)
  6. Melanoma and Immunotherapeutics Service (793)

More Groups

People
  1. Klaus Busam (698)
  2. Daniel Coit (543)
  3. Allan Halpern (401)
  4. Michael Postow (369)
  5. Alexander Shoushtari (247)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (89)
  2. 2024 (138)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (269)
  2. Annals of Surgical Oncology (221)
  3. Journal of the American Academy of Dermatology (123)
  4. Journal of Investigative Dermatology (84)
  5. Modern Pathology (67)
  6. American Journal of Surgical Pathology (64)

More Publications

Publishers
  1. Springer (341)
  2. American Society of Clinical Oncology (284)
  3. Elsevier Inc. (231)
  4. Lippincott Williams & Wilkins (229)
  5. Wiley Blackwell (162)
  6. Elsevier Science, Inc. (160)

More Publishers

Results (2770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy
    Journal Article

    Bai, X.; Hu, J.; Betof Warner, A.; Quach, H. T.; Cann, C. G.; Zhang, M. Z.; Si, L.; Tang, B.; Cui, C.; Yang, X.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Phenotyping tumor-immune microenvironment (TiME) in vivo in patients using reflectance confocal microscopy
    Conference Paper

    Sahu, A.; Gill, M.; Cordova, M.; Santella, A.; Kose, K.; Tembo, T.; Alfonso, A.; Chandrani, P.; Wang, A. W.; Fox, C.; more...
    Optical Society of America (2021)

    Fulltext@MSK | Save
  • Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
    Meeting Abstract

    Shoushtari, A. N.; Collins, L.; Espinosa, E.; Sethi, H.; Stanhope, S.; Abdullah, S.; Ikeguchi, A.; Ranade, K.; Hamid, O.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Biomarkers of response and hyperprogression in patients with sarcoma treated with checkpoint blockade
    Meeting Abstract

    Klemen, N. D.; Hwang, S.; Bradic, M.; Rosenbaum, E.; Dickson, M.; Gounder, M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Thornton, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
    Meeting Abstract

    Margolin, K. A.; Korn, R.; Farwell, M.; Postow, M. A.; Hays, D.; Wilson, I. A.; Le, W. H.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
    Meeting Abstract

    Shoushtari, A. N.; Olszanski, A. J.; Nyakas, M.; Hornyak, T. J.; Wolchok, J. D.; Levitsky, V.; Møller, A. S.; Kuryk, L.; Handeland, K. R.; Jäderberg, M.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
    Meeting Abstract

    Dummer, R.; Long, G. V.; Pavlick, A. C.; Postow, M. A.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J. M.; Tetzlaff, M.; Su, S. C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
    Meeting Abstract

    Tawbi, H. A.; Forsyth, P. A.; Hodi, F. S.; Algazi, A.; Hamid, O.; Lao, C. D.; Moschos, S. J.; Atkins, M. B.; Lewis, K.; Postow, M. A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
    Meeting Abstract

    Bhave, P.; Ahmed, T.; Shoushtari, A. N.; Zaremba, A.; Versluis, J. M.; Mangana, J.; Weichenthal, M.; Si, L.; Lesimple, T.; Robert, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • An open-label, phase II, multicenter, single-arm study of induction and concurrent vismodegib combined with curative-intent radiation therapy for locally advanced basal cell carcinoma
    Meeting Abstract

    Yom, S.; Arron, S.; Ho, A.; Algazi, A.; Dunn, L.; Tsai, C. J.; Humphries, A.; Hultman, C.; Grekin, R.; Knott, P. D.; more...
    American Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save